Scientists identify a molecular switch to a painful side effect of chemotherapy
Peer-Reviewed Publication
Updates every hour. Last Updated: 21-Dec-2025 06:11 ET (21-Dec-2025 11:11 GMT/UTC)
A research team led by Professor Eijiro Miyako at the Graduate School of Advanced Science and Technology, Japan Advanced Institute of Science and Technology (JAIST), has discovered that the marine bacterium Photobacterium angustum demonstrates remarkable therapeutic efficacy against colorectal cancer.
Through screening of multiple marine bacterial strains, the researchers found that P. angustum, in its natural, non-engineered form, selectively accumulates in tumor tissues and induces both direct tumor lysis and robust immune activation. In mouse models, intravenously administered P. angustum showed high tumor tropism while exhibiting minimal colonization of vital organs except the liver, with no hematological abnormalities or histological toxicity observed.
Furthermore, P. angustum therapy promoted intratumoral infiltration of immune cells including T cells, B cells, and neutrophils, and enhanced production of inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). The bacterium also demonstrated intrinsic oncolytic activity through natural exotoxin production, directly destroying cancer cells. These combined mechanisms significantly prolonged survival in treated mice, with complete remission achieved in some cases.
This research represents a critical advance toward developing safer, more biocompatible cancer immunotherapies that do not rely on genetically modified organisms (GMOs).
The study has been accepted for publication in the Journal for ImmunoTherapy of Cancer, a leading international journal in the field of cancer immunotherapy.
New research from Memorial Sloan Kettering Cancer Center (MSK) finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing safer and more reliable; and shows provider billing margin doesn’t drive cancer treatment selection.
Traces of bacteria were found inside of brain tumors, which could impact tumor behavior
Inflammation drives early-stage lung cancer, and targeting inflammatory pathways could be a therapeutic strategy
HSP90 can mask negative effects of BRCA1 mutations, presenting a target to help overcome treatment resistance
A patented RNA-based cocktail developed at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has emerged as a promising active agent against tumors of the central nervous system, such as glioblastoma. The study, published today in the scientific journal Molecular Therapy – Nucleic Acids, demonstrates the effectiveness of a combination of 11 different non-coding RNAs, known as microRNAs (miRNAs), in slowing the growth of cancer cells and enhancing the activity of chemotherapeutic drugs. Tests were carried out on patient-derived cells and on preclinical models. Further validation steps will be required for medical use of the compound.
Cervical cancer will be the first human cancer eliminated through coordinated global action. A new special issue of Cancer Biology & Medicine brings together leading experts from around the world to examine progress, challenges, and innovations in prevention, screening, and treatment.
A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer.
McGill University researchers at the Rosalind and Morris Goodman Cancer Institute (GCI) identified a mechanism driving neuroendocrine prostate cancer, a rare and highly aggressive subtype for which there currently are no effective treatment options.
Cancer research, drug safety testing and ageing biology may all gain a major boost from a new fluorescent sensor developed at Utrecht University. This new tool allows scientists to watch DNA damage and repair unfold in real time inside living cells. The development, which opens the door to experiments that weren’t feasible before, is published today in the journal Nature Communications.